

## REFERENCES

- 1 Acocella G. [1983] Rifamycin. *G Ital Chemioter* (30) 1 1-24.
- 2 Agrawal Y (1990) Statistical Methods: Concepts, Applications and Computation. Pub. By Sterling Publishers Pvt. Ltd., New Delhi.
- 3 Akimoto T, Ono K and Nanpo T [1970] Absorption, distribution, metabolism and excretion of rifampicin(rifamycin SV) in the rat. *Jpn J Antibiot* (23) 3 250-256.
- 4 Assandri A, Cristina T and Moro L (1978) Physiological deposition of a series of rifamycin in rat: A comparative study. *J Antibiotiki* (31) 9 894-901.
- 5 Attari S, Rana S, Vaiphei K, Sodhi, Katyal R, Goel R, Nain C & Singh K (2000) Isoniazid and Rifampicin induced oxidative hepatic injury protection by N-acetylcysteine. *Hum Exp Tox* (19) 517-522.
- 6 Attari S, Rana S, Vaiphei K, Katyal R, Sodhi C, Kanwar S & Singh, K. (2001) Protective effect of N-acetylcysteine in Isoniazid induced hepatic injury in growing rats. *In Press*
- 7 Avachat M, Rambhau D, Sarveswar Rao V, Ramesh Rao B & Venkateshwar Rao, J. (1992) Pharmacokinetics of Rifampicin. *Ind J Physiol Pharmacol* (36) 4 251-254.

- 8 Bergmeyer U H [1965] Phosphatases, in *Methods of Enzymatic Analysis*. Academic press, London, p. 779
- 9 Binda <sup>other names</sup> et al (1971) Review of methods for determining rifampicin in body fluids. *Arzeimittel-Forsch (21)* 1907.
- 10 Bruzzese T, Rimaroli C, Bonabello A, Mozzi G, Ajay S and Coovraj N [2000] Pharmacokinetics and tissue distribution of rifametane, a new 3-azinomethyl-rifamycin derivative, in several animal species. *Arzneimittel-Forschung (50)* 1 60-70.
- 11 Buege J A and Aust S D (1978) Microsomal lipid peroxidation. *Methods in Enzymology*, 52, 304 -310 *Editor*
- 12 Chung S, Gumienny T L, Hengartner M O and Driscoll M (2000) A common set of engulfment genes mediates removal of both apoptotic and necrotic cell corpses in *C. elegans*, *Nature Cell Biol*, 2, 931 - 937
- 13 Cooper D, Levin S, Narsimhulu S, Rosenthal O and Estahrook R W (1965) *Science (147)* 400.
- 14 Dahanukar S, Kapadia A, & Karandikar S (1983) Influence of trikatu powder on Rifampicin bioavailability. *Ind Drugs (20)* 402-404.
- 15 Devershi P, Kanase A, Mane S, Patil S & Varute A (1986) Effect of Mandur bhasma on lypolytic enzymes of liver, kidney, and adipose tissue of albino rat during CCl<sub>4</sub> induced hepatic injury. *J Biosciences (10)* 227-235. *Differ bet. 15 and 41*

- 16 Dworkin L D and Brenner B M (1985) Biophysical basis of glomerular filtration, in, The Kidney-physiology and Pathobiology, Ed by Seldin DW and Giebisch G, Pub by Raven Press New York 397-426
- 17 Elias H and Sherrick J (1968) in 'Morphology of the liver' Pub by Academic Press, New York, London.
- 18 Ellard G and Fowrie P [1999] Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. *Int J Tuberc Lung Dis* (3) 301-308.
- 19 Farris E and Griffith (Jr) J (1971) The rat in laboratory investigation. Pub by Hafner Publishing Company, New York.
- 20 Fekety et al [1983] *Rev infect Dis* (5) 523.
- 21 Filippovs'iants S, Kunrat I and Gol'dberg L [1980] Pharmacokinetics of tobramycin and gentamycin and the mechanism of their elimination by the kidneys. *Antibiotiki* (25) 8 579-584.
- 22 Firsov A, Umnova L, Stepanov V & Fomina I [1986] Modelling of rifampicin pharmacokinetics in experimental animals administered the drug intravenously and internally. *Antibiot Med Biotekhnol* (31) 445-449.
- 23 Fisher R and Yates F (1938) Statistical Tables. Pub. by Oliver and Boyd Edinburgh.

- 24 Frontali L and Tecce G [1967] Rifamycins-Mechanism of Action in "Antibiotics, Vol -I" Ed by David Gottlieb and Paul D. Shaw. 415-426.
- 25 Frontali L & Tecce G (1967) <sup>to</sup> "Rifamycins." In Antibiotics Vol. I-Mechanism of Action. Ed. By Gottlieb, D. and Paul D. Shaw. Pub by Springer-Verlag. P. 415-426. <sup>What is the diff. bet - these two referen</sup>
- 26 Gebhardt R (1992) Metabolic zonation of the liver: regulation and implications for liver function. *Pharmacol Ther*, 53, 275-354
- 27 Girling D J (1978) The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. *Tubercle* (59) 13-32
- 28 Girling D and Hitze K [1979] adverse reactions to rifampicin. *Bull World Health Organ* (57) 1 45-49.
- 29 Goldberg I H and Friedman, P A (1971) Antibiotics and nucleic acids. *Ann.Rev.Biochem.* 40 775-810.
- 30 Grunert R R and Phillips R R (1951) Determination of Glutathione *Arch Biochem*, 30, 217.
- 31 Gupta P K (1983) Mechanisms of drug induced liver toxicity. Part I and II. *Ind Drugs* (20) 4 123-139.
- 32 Gupta S K, Maini V K and Bedi R S [1983] Adverse Reactions with Multiple Anti-TB Drugs. *Ind J Tub* (30) 162-165.
- 33 Gumucio J and Chianale J (1988) in 'The Liver: Biology and Pathobiology' Ed by Arias I, Jacoby W, Popper H and Schfritz D Pub by Ravan Press, 931-947.

- 34 Guyton A (1992) Lipid and protein metabolism in *Human Physiology and Mechanisms of Disease*. Pub by W B Saunders company, Philadelphia.
- 35 Heinegard and Tiderstorm (1973) *Clin Chim Acta* (43) 305.
- 36 Henry J B (1991) in "Clinical diagnosis and management by laboratory methods." Pub. by W. B. Saunders Company, London.
- 37 Hildebrant A, Tjoe M and Root I (1975) *Biochem Soc Trans* (3) 807.
- 38 Hinton R and Grasso P [1995] Hepatotoxicity, in 'General and Applied Toxicology' Ed by Ballantyne B, Marrs T and Turner P. Pub by MacMillan Press, Ltd. London.
- 39 Iakovlev VP [1978] Pharmacokinetics of rifampicin. *Antibiotiki* (23) 526-33.
- 40 Jendrassik L and Grof P [1938] Simplified photometric method for the determination of the blood bilirubin. *Biochem J* (297) 81
- 41 Kanase A, Patil S & Kulkarni P (1992) Effect of Mandur bhasma on lyolytic enzymes of liver, kidney and adipose tissues of albino rats during CCl<sub>4</sub> induced hepatic injury. *Deerghayu Int* (8) 4 11-17.
- 42 Kanase A, Patil S & Thorat B (1997) Curative effects of Mandur bhasma on liver and kidney of albino rats after CCl<sub>4</sub> induced liver injury. *Ind J Exp Biol* (35) 754-764.
- 43 Katz and Lor [1986] Acute interstitial nephritis associated with intermittent rifampin use. *Drug Intell and Clin Pharm* (20) 789.

- 44 Kenny M and Strates B [1981] Metabolism and pharmacokinetics of the antibiotic rifampin. *Drug Metab Riv* (12) 159-218.
- 45 Kersten H & Kersten W (1979) in "Inhibition of nucleic acid synthesis." Pub by Springer-Verlag, Berlin *Editor*
- 46 Khedun S, Maharaj B, and Leary W. (1992) The effects of supratherapeutic doses of Rifampicin on liver function in the perfused rat liver. *Int J Exp Path* (73) 449-453.
- 47 Koroleva and Fomina (1976) Pharmacokinetics of rifampicin in experimental animals. *Antibiotiki* (21) 722-725.
- 48 Krishna D, Appa Rao A and Ramanakar (1984) Pharmacokinetics of Rifampicin in the presence of Prednisolone in leprosy patients. *Ind Drugs* (21) 369-373.
- 49 Krishnamurthy C.R. (1985) in "Modern Toxicology." Vol I Ed by Gupta P.K. and Salunkhe D.K. Pub by Metropolitan Book Co. Pvt. Ltd. New Delhi. P.95.
- 50 Lal S, Singhal S, Burley D and Crossley G (1972) Effect of Rifampicin and isoniazid on liver function. *Bri Med J* (1) 148-150.
- 51 Le Guellec C, Gaudet M, Lamanetre S and Breteau M [1997] Stability of rifampin in plasma: consequences for therapeutic monitoring and pharmacokinetic studies. *Ther Drug Monit* (19) 669-674.
- 52 Lehninger A L (1984) in "Biochemistry" Pub. by M\ S Worth Publishers Inc. New York. *page 400*

- 53 Levine R L, Garland D, Oliver S, Amici A, Ccliment I, Lenz A G, Ahn B W, Shaltiel S and Stadtman E R (1990) 'Determination of Carbonyl Content in Oxidatively Modified Proteins' Assay and Repair Of Biological damage. in *Methods Of Enzymology (186)*
- 54 Levy G [1980] Clinical implications of interindividual differences in plasma protein binding of drugs. *Acta Pharmaceut Sci (17)* 92-94.
- 55 Lock E A [1995] Responses of the kidney to toxic compounds in general and applied toxicology. In " General and Applied Toxicology" Ed. by B Ballentyne, Marrs T and Turner P Pub by MacMillan Press Ltd. London. 443-472.
- 56 Louden [1972] The Place of Rifampicin. *Chest (61)* 524-525.
- 57 Lowry O, Rosenbergh N, Farr A & Randoll R (1951) Protein measurement with Folin-Phenol reagent. *J Biol Chem (193)* 265-275.
- 58 Maffii G, Schiatti P, Bianchi G and Serralunga M [1961] Rifomycin XVII. Pharmacological studies with rifomycin SV. Changes in respiratory activity of mitochondria induced by rifomycins. *Farmaco Ed Sci (16)* 235.
- 59 Mahajan M, Rohotgi D, Talwar V, Patni S, Mahajan P and Agarwal D [1997]. Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis. *J Commun Des. (29)* 269-274.
- 60 Martindale - The extra pharmacopeia [1989].

- 61 Matsumoto K and Nakamura T (1992) Growth factor: molecular structure, role in liver regeneration and other biological functions. *Crit Rev Oncog* (3) 27-54.
- 62 Maunsbach A B (1980) Functional ultrastructure of the kidney. Pub. By Academic press, London
- 63 May H and McCay P (1968) Reduced triphosphopyridine nucleotide oxidase-catalysed alterations of membrane phospholipids. *J Biol Chem* (243) 2288-2293.
- 64 Mehendale H (1979) Modification of hepatobiliary function by toxic chemicals. *Fed Proc* (38) 2240 2245.
- 65 Mehendale H M (1985) in "Modern Toxicology" Vol I Ed. by Gupta P.K. & Salunkhe D K Pub.by Metropolitan Book Co. Pvt. Ltd. New Delhi.
- 66 Melby (Jr) E and Altman N (1977) Handbook of Laboratory Animal Science Vol I, II, III Ed by Melby E (Jr), Altman N Pub by CRC Press Inc Ohio 44128 USA.
- 67 Mishra S (1984) 'Rasendra Chudamani' Pub by Chowkhamba Orientalia, Varanasi
- 68 Nebert D W and Negishi M (1982) Multiple forms of cytochrome P-450 and the importance of molecular biology and evolution. *Biochem Pharmacol* (31) 2311-7
- 69 Nebert D et al (1983)
- 70 Nebert D Peterson D and Foruse A (Jr) (1993) *Environ Health Prospect* (88) 33-35.



- 71 Nebert D and Gonzalez F (1987) P-450 genes: Structure, evolution and regulation. *Ann Rev Biochem* (56) 945.
- 72 Nessi R, Bonoldi GL, Redaelli B, di Filippo G (1976) Acute renal failure after rifampicin: a case report and survey of the literature , *Nephron* (16) 148-59
- 73 Oinonen J, and Lindros K (1995) Hormonal regulation of the zoned expression of cytochrome P-450 3A in rat liver. *Biochem J* (309) P 55.
- 74 Olatunde F, Akinloye O, Akinmoladum C & Emerole G (1999) Hepatic drug metabolising enzyme induction and serum triglycerol elevation in rats treated with Chlorzepoxide, Griseofulvin, Rifampicin and Phenytoin. *Clin Chim Acta* (289) 1-10
- 75 Oshino N, Chance B, Sies H and Bichner T (1973) Role of hydrogen peroxide generation in perfused rat liver and the reaction of catalase compound I and hydrogen donors. *Arch Biochem Biophys* (154) 117-131.
- 76 Patel R, Gandhi T, Shah G, Patel V, and Gilbert R [1981] Resorption Profiles of Amoxicillin, Glimbenclamide, Chlorpropamide & Tolbutamide by Desaga Rosamat I & II. *Ind Drugs* (18) 357-364.
- 77 Pears A. G. E. (1968) Histochemistry, 3<sup>rd</sup> Edition. Pub. by Little Brown and Co. Boston.
- 78 Pharmaceutical codex [1979].

- 79 Piriou A, Warnet J, Jaqueson A, Claude J and Truhaut R [1979] Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukaryotic cells. *Arch Toxicol Suppl (2)* 333-337.
- 80 Piriou A, Jaqueson A, Warnet JM & Claude JR (1980). Study of the protective effect of an anabolic steroid, 19-nortestosterone phenylpropionate( 19-NTPP) on the fatty liver induced by high doses of rifampicin in the rat. *Arch Toxicol Suppl (4)* 331-334.
- 81 Piriou A, Jaqueson A, Warnet J & Claude J (1983) Enzyme induction with high doses of Rifampicin in Wistar rats. *Toxicol Lett (1983)* 301-306.
- 82 Piriou A, Maissiat R, Jaqueson A, Warnet J & Claude J R (1987) Ultrastructural changes in the parenchymal liver cells of rats treated with high doses of rifampicin. *Br J Exp Pathol (68)* 201-207.
- 83 Polasa K & Krishnamurthy Y (1987) In-vitro studies on protein binding of Rifampicin. *Ind J Pharmacol (19)* 225-229.
- 84 Poulsen L, Kadluber F and Ziegler D (1974) *Arch Biochem Biophys (164)* 774.
- 85 Puri S and Kohli K (1995) Difference in drug metabolizing enzymes and their response to lindane in rat, rabbit and monkey. *Pharmacol Toxicol (77)* 136 -141.
- 86 Rajan M, Sunderajan R, Krishnamurthy V & Ramu G (1987) Acute renal failure following Rifampicin. *Ind J Lepr (59)* 286-292.

- 87 Ramakrishnan T and Chandrashekhar P (1999) The control of tuberculosis: a continuous game of snakes and ladders. *J Biosci (24)* 143-152.
- 88 Ramana K and Kohli K (1999) Effect of co-administration of anti-tuberculous drugs on the hepatic drug metabolising enzymes and oxidative stress in the mouse. *Ind Jr Pharmacol (31)* 299-305.
- 89 Rana S, Sodhi C P, Mehta S, Vaiphei K, Katyal R, Thakur S, Mehta S K (1996) Protein-energy malnutrition and oxidative injury in growing rats. *Hum Exp Toxicol (15)* 810-4
- 90 Rao N, Wadia R, Karve A, & Grant K (1982) Hepatotoxicity of antituberculous drugs. *J Asso Phys Ind (5)* 195-198.
- 91 Reckngel R & Glende E (1978) in "Handbook of Physiology," Section-9. Ed. by Lee H, Falk H & Murphy S. Pub. by American Physiol Soc Washington, D. C. P.591-602.
- 92 Reitman S and Frankel S A [1957] A calorimetric method for the Determination of serum glutamate oxaloacetate and glutamate pyruvic transaminase. *Am J Clinical Pathology (28)* 56
- 93 Riva S and Silvestri L [1972] Rifamycin: A general view. *Ann Rev Microbiol (26)* 119-124.
- 94 Rodriguez G, Morisoli L, Spetele M and Rasserero J [1973] Metabolism of rifampicin II. Distribution of rifampicin and its metabolites in normal rats and in rats with changes in the liver. *Farmaco (Prat) (28)* 489-496.

- 95 Roullier C H [1963] Experimental toxic injury of the liver. *In The Liver, Ed by C H Roullier* Published by Academic Press New York vol. 2, pp. 335-443
- 96 Roullier C Muller A [1969] The Kidney, Vol 1-4 Pub by Academic Press, London.
- 97 Sallie R, Tredger J and Williams R [1991] Drugs and liver. Part 1: Testing liver function. *Biofarm Drug Dispos (12)* 251-259.
- 98 Saraswathy S, Suja V, Gurumurthy P & Shymala Devi C. (1998) Effect of LIV-100 against antitubercular drugs (Isoniazid, Rifampicin and Pyrazinamide) induced hepatotoxicity in rats. *Ind Jr Pharmacol (30)* 233-238.
- 99 Sawiki E & Sawiki C (1975) in "Aldehydes Photometric Analysis." Vol 1 Pub. by Academic Press, New York. P.210.
- 100 Sensi P, Greco A & Ballota R [1959] Rifomycins. I. Isolation and properties of rifomycin B and rifomycin complex. *Antibiotics Ann* 262.
- 101 Sharma S [1977] *Rasa Ratna Samuchhaya* Published by Motilal Banrasidas, New Delhi pp. 72-108
- 102 Shacter E (1999) Quantitation and significance of protein oxidation in biological samples. *Drug Metab Rev. (33)* 307-26.
- 103 Shaha A, Banerjee S & Agrawal Y (1983) Spectrophotometric estimation of Rifamycin in biological fluids. *Ind Drugs (21)* 66-69.

- 104 Shapovalov V, Mil'Čenko K & Kovalenko N. (1982) Experimental pharmacodynamic study of Rifampicin administered by various methods. *Antibiotiki* (27) 434-437.
- 105 Silvestri [1970] RNA -polymerase and transcription. Pros of the I Int Lepetit Coll Ed by Silvestri, Pub by North Holland Publications, London. pp 1-339.
- 106 Singh N, Srivastava A, Mathur I, Gupta H & Gupta S (1981) Effect of Rifampicin treatment on Mycobacterium avium infection in CCl<sub>4</sub> treated rabbits. *Ind J Exp Bio* (19) 201-202.
- 107 Skakun N P & Shaman'ko V. (1985) Synergistic effect of Rifampicin on hepatotoxicity of Isoniazid. *Antibiot Med Biotechnol* (30) 85-89.
- 108 Skakun N P and Slivaka Y (1992) the correlation of the hepatotoxicity of antitubercular preparations with tocopherol acetate and riboxin. *Eksp Klin Farmakol* (55) 52-54.
- 109 Skakun N & Tabachuk O (1992) The comparative action of Isiniazid, Rifampicin and Ethambutamol on liver function. *Eksp Klin Farmakol* (55) 45-47.
- 110 Slater T. F. (1978) in "Biochemical Mechanism of Liver Injury.", Pub. by Associated Press, New York. P. 1-95.

- 111 Slivaks I I, Klimniuk E V and Tabachuk O E (1989) Comparative characterization of the hepatotoxicity of isoniazid, rifampicin and pyrazinamide. *Farmacol Toxicol* (52) 82-85.
- 112 Slivka I I (1989) Comparative characterization of the hepatotoxicity of isoniazid, rifampicin and pyrazinamide. *Farmakol Toksikol* (52) 82-85
- 113 Sodhi C, Rana S, Mehta S, Vaiphei K, Attari S , Thakur S, & Mehta S (1996) Study of oxidative stress in Isoniazid- induced hepatic injury in young rats with and without protein-energy malnutrition. *J Biochem Toxicol* (11) 139-46.
- 114 Sodhi C, Rana S, Mehta S, Vaiphei K, Attari S & Mehta S (1997<sub>a</sub>) Study of oxidative stress in Isoniazid- Rifampicin induced hepatic injury in young rats. *Drug Chem Toxicol* (20) 255-269.
- 115 Sodhi C, Rana S, Mehta S, Vaiphei K, Goel R & Mehta S (1997<sub>b</sub>) Study of oxidative stress in Rifampicin induced hepatic injury in growing rats with and without protein energy malnutrition. *Hum Exp Toxicol* (16) 315-321.
- 116 Sodhi C, Rana S F, Attari S, Mehta S, Yailphei K, Mehata S K. (1998) Oxidative - hepatic injury of isoniazid-rifampicin in young rats subject to protein and energy malnutrition. *Drug chem Toxicol* (21) 305-17.
- 117 Stonrad M and Evans G (1995) Clinical Chemistry, in' General and applied toxicology' Ed by Ballantyne B, Marrs T and Turner P Pub by MacMillan Press Ltd. London, p. 247.

- 118 Strolin M and Dostert P [1994] Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. *Environ Health Perspect* (102) 101-105.
- 119 Subbotina N, Gariaznova N, Beliavskaia I, Sazykin I and Navashin S [1979] Pharmacokinetics and biotransformation of rifamycins in the body of experimental animals. *Antibiotiki* (24) 590-597.
- 120 Sundseth S and Waxman D (1992) Sex dependent expression and clofibrate inducibility of cytochrome P-450A fatty acid omega hydrolases. Male specificity of liver and kidney cyp4A2 mRNA and tissue specification regulation by growth hormone and testosterone. *J Biol Chem* (267) 3915-3921.
- 121 Sunhara/and Nagakawa/<sup>initials</sup>[1972] Metabolic Study and Controlled Clinical Trials of Rifampin. *Chest* (61) 526-532.
- 122 Talwar G (1980) Textbook of Biochemistry and Human Biology. Pub by Prentice Hall of India Pvt Ltd. New Delhi, 110001. *Page*
- 123 Thompson S.W. (1966) Selected Histochemical and Histopathological Methods. Pub. by Thomas C.C. Springfield, U.S.A. *Page*
- 124 Timbrell J A [1995] Biotransformation of Xenobiotics. In "General and Applied Toxicology" Ed by B Ballentyne, Marrs T & Turner P. Pub by MacMillon Press Ltd. London, p.79-109.
- 125 Truhaut R, Claude J, Warnet J, Jacqueson A and Piriou A [1978] Liver steatogenic power of high doses of rifampicin in rats. *C R Acad Sci Hebd Seances Acad Sci D* (286) 493-497.

- 126 Tuchmann-Duplessis H, Mercier\_Parot L (1969) Influence of an antibiotic, rifampicin, on the prenatal development of rodents. *C R Acad Sci Hebd Seances*
- 127 Venkatraman P, Narayana A & Prabhakar R [1988] Simple Qualitative Tests for Rifampicin in Urine. *Ind J Tub (35)* 114-116.
- 128 Venturini A [1983] Pharmacokinetics of L\105, a new rifamycin, in rats and dogs, after oral administration. *Chemotherapy (29)* 1-3.
- 129 Waxman D and Azaroff L (1992) Phenobarbitone induction of cytochrome P-450 gene expression. *Biochem J (281)* 577.
- 130 Werringloer J (1978) assay of formaldehyde generated during microsomal oxidation reactions. *Methods in Enzymology, 52*, 297-302
- 131 Wills E (1971) Effects of lipid peroxidation on membrane bound enzymes of the endoplasmic reticulum. *Biochem J (123)* 983.
- 132 Winsel K, Iwainsky H, Werner E, Eule H (1976) Separation, determination and pharmacokinetics of rifampicin and its biotransformation products, *Pharmazie (31)* 95-99
- 133 Wise R [1983] Protein binding of betalactams: The effects on activity and pharmacology, particularly tissue penetration. *J Antimicrob Chem (12)* 1-18.
- 134 Wu C & Stohs S (1983) Non comparative inhibition of hepatic and intestinal aryl-hydrocarbon hydroxylase activities from rats by Rifampicin. *J Nat Prod (46)1* 108-111.



- 135 Yan B [1982] Observation on absorption and elimination of rifamdin in man. *Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi* (5) 71-73.
- 136 Zhang J N, Liu X G, Zhu M, Chiu F C and Li R C (1998) Assessment of pre-systemic factors on the oral bioavailability of rifampicin following multiple dosing. *J Chemother* (10) 354 - 359
- 137 Zwolska- Kwiec Z, Ceglecka-Tomaszewska K and Ziolkowski J [1982] Serum rifampicin level in children with tuberculosis and in young mice. *Pneumonol Pol* (50) 571-579.
- 138 Zitcova L, Statsna J, Dobrovsky K and Tousek J [1982] Cause for rifampicin toxicity - experimental study. *Czech Med* (5) 210-217.
- 139 Zhou Z, Hartweg E and Horvitz HR (2001) CED-1 Is a Transmembrane Receptor that Mediates Cell Corpse Engulfment in *C. Elegans*. *Cell* (104) 43-56.